Brian Pacampara, CFA
Brian Pacampara's Articles
Takeover Talk Surrounds Bristol-Myers Squibb My ears always perk up when takeover rumors swirl, especially when they involve large-cap dividend stocks. The latest big buyout buzz came on Tuesday, when Bristol-Myers Squibb Co (NYSE:BMY) stock popped three percent on whispers.
I typically advise our readers to shy away from red-hot momentum stocks, especially large ones. The Texas Instruments dividend stock, for instance, is up a whopping 48% over the past year, easily outpacing the Dow’s return (at the time of.
Sometimes, the market makes things easy for us. After a somewhat sluggish 2016, Procter & Gamble Co (NYSE:PG) stock is on a nice little run of late, up more than four percent year-to-date and about 11% above from its 52-week.
It’s never a good idea to stereotype, even when it comes to stocks. Income investors, for example, might have completely ignored Starbucks Corporation (NASDAQ:SBUX) over the years due to the largely held belief that it remains a trendy, high-multiple-growth play.
No business is immune to disruption—not even one that has sold syrupy soft drinks since 1892. Often the bedrock of conservative dividend portfolios, The Coca-Cola Co (NYSE:KO) stock is down about 15% from its 52-week highs amid slumping revenue and.
Never lose interest in a stock simply because of a low dividend yield. For instance, it would’ve been pretty easy for income investors to pass on Visa Inc (NYSE:V) stock and its regularly paltry sub-one-percent dividend yield in recent years..
Companies can often be the victims of their own success. Gilead Sciences, Inc. (NASDAQ:GILD) stock, for example, skyrocketed roughly 400% from 2012 to 2016 thanks to a quadrupling of revenues over the same time period. However, a recent string of.
Nothing gets my attention quite like a large-cap dividend payer whose stock is slumping. Exxon Mobil Corporation (NYSE:XOM) stock, for instance, is down roughly 10% year-to-date and off about 15% from its 52-week highs. Now, that might not be such.
It’s been a painful year for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock owners. A string of strategic missteps, delayed drug launches, and legal headaches amid the increasingly competitive generics market have sent the Teva stock shares down a whopping.
The market giveth and the market taketh away. After a white-hot three-month run, General Motors Company (NYSE:GM) stock is now down to its lowest level since the first trading day of 2017. So what’s going on? Well, last week, the.